Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Dutton Associates Featured Company: NexMed, Inc. (NEXM)

NexMed, Inc. (NASDAQ: NEXM) engages in producing innovative medical treatments by utilizing their proprietary NexACT® drug delivery technology. The company works with large pharmaceutical companies offering their NexACT® drug delivery technology to be incorporated into existing drugs, allowing these companies to save enormously on research and development costs while developing new patient-friendly products which extend patent life-spans and brand equity. NexMed has partnerships with Novartis International Pharmaceutical Ltd. for licensing and marketing Onychomycosis treatment, an anti-fungal drug, and a licensing agreement with Warner Chilcott, Ltd. for exclusive rights to their topically applied treatment for erectile dysfunction (ED).

NexACT is the company’s transdermal drug delivery technology, which represents an important medical advancement that provides a more effective approach to the diseases that are currently being treated by systemic (oral or intravenous injections) therapy. By utilizing highly effective formulations that consist of new biodegradable ingredients, these drugs breakdown the skin’s natural barrier properties more naturally, which results in an increased rate of penetration carrying concentrations of active drugs directly through the skin and major mucous membranes, ultimately resulting in new and effective topical and transdermal therapies. The NexACT technology offers a wide range of applicability in the development of transdermal dosage forms such as patches, creams, gels, ointments, lotions, solutions, and intranasal sprays.

NexACT technology offers several competitive advantages in the treatment of various illness including: fast onset of action, patient-friendly route of delivery, little or no side effects, and improved clinical efficacy. It also may offer significant clinical benefits if low bioavailabilty, multiple daily dosing, liver first-pass effect, or gastrointestinal side effects are associated with oral or injection dosage forms.

Let us hear your thoughts: NexMed, Inc. Message Board

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *